Transepithelial photorefractive keratectomy enhancement for myopic regression

Uncorrected refractive errors are a major global public health concern, responsible for approximately 50% of visual impairments. Surgical options such as photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK) are effective but can result in myopic regression, necessitating retreatment. To evaluate the efficacy, safety, and predictability of transepithelial PRK (Trans-PRK) for correction of myopic regression after previous refractive surgery.

Trans-PRK was performed in eyes with myopic regression after previous PRK or LASIK with a mean refractive spherical equivalent (SE) of - 1.92 diopter (D) ±0.96 (standard deviation). The mean preoperative logMAR uncorrected distance visual acuity (UDVA) was 0.59 ± 0.38. Postoperative evaluation included UDVA, SE, epithelial healing, and haze formation at 1 week, 2 months, and 6 months.

The study evaluated 26 eyes of 15 patients. At 6 months postoperatively, the proportion of eyes within ± 0.50 D and ± 1.00 D of the target refraction was 37.5% and 100%, respectively. After the enhancement, the percentage of eyes with Snellen UDVA of 20/20 or better was 80% at 6 months, while all of the eyes had a Snellen UDVA of 20/25 or better. The mean postoperative SE was - 1.01 ± 0.74, at 1 week, -0.61 ± 0.98 at 3 months, and - 0.38 ± 0.57 at 6 months. No significant complications were noted.

The results of this study indicate that Trans-PRK appears to be safe, effective, stable, and predictable procedure for the treatment of myopic regression after previous PRK or LASIK.